RESEARCH ARTICLE

Signs of left atrial disease and 10-year risk of atrial fibrillation

Tobias Uhe¹*, Tina Stegmann¹, Romy Langhammer¹, Nikolaos Dagres², Ulrich Laufs¹, Rolf Wachter¹

¹ Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany, ² Abteilung für Rhythmiologie, Herzzentrum Leipzig, Leipzig, Germany

* Tobias.Uhe@medizin.uni-leipzig.de

Abstract

Background
The contribution of left atrial disease and excessive supraventricular ectopic activity (ESVEA) to the risk for incident atrial fibrillation (AF) is incompletely understood.

Objective
To analyse the ten-year risk to develop AF in patients with cardiovascular risk factors and to define the impact of parameters of left atrial disease and ESVEA on AF risk.

Methods
148 patients from the Diast-CHF trial with at least one cardiovascular risk factor and free of AF at baseline were followed for 10 years. Left atrial disease was defined as left atrial volume index (LAVI) >35 ml/m², P-terminal force in lead V₁ (PTFV₁) >4000 ms*μV or elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) >250 pg/ml. We analyzed the association of these parameters and ESVEA (either >720 premature atrial contractions (PAC) or one atrial run >20 beats per day) on AF-free survival.

Results
After ten years, AF was newly detected in twelve patients (13.4%) with signs of left atrial disease and two patients (3.4%) without signs of left atrial disease (p = 0.04). LAVI (p = 0.005), ESVEA (p = 0.016) and NT-proBNP (p = 0.010) were significantly associated with AF-free survival in univariate analysis. A combined Cox model of left atrial disease parameters showed associations for NT-proBNP (HR 3.56; 95%CI 1.33–5.31; p = 0.04) and PAC (HR 2.66; 95%CI 1.25–5.31; p = 0.04) but not for LAVI or PTFV₁ with AF-free survival.

Conclusion
The risk for AF is higher in patients with cardiovascular risk factors and signs of left atrial disease. NT-proBNP and premature atrial contractions independently predict AF-free survival.
The role of excessive supraventricular ectopic activity for the assessment of AF risk may be underestimated and requires further study.

1. Introduction

Atrial fibrillation (AF) is the most common rhythm disorder and one of the major risk factors for ischemic stroke. Several risk factors for AF have been identified and recently, the concept of left atrial cardiomyopathy (LACMP) has been developed and proposed to play a key role in the development and progression of AF [1]. However, the definition of LACMP or left atrial disease is a matter of discussion and the impact of its components on AF risk has not been studied in detail. The risk of AF is increased with age and cardiovascular comorbidities [2]. Biomarkers reflecting left atrial abnormalities, e.g., enlargement or fibrosis have been proposed and shown to improve AF risk stratification. The most established biomarkers are echocardiographic and electrocardiographic indicators for enlargement of the left atrium and natriuretic peptides [3].

Echocardiographic left atrial enlargement measured in one dimension has been shown to be a predictor of AF in the Framingham Heart Study and Cardiovascular Health Study [4, 5]. Moreover, Tsang et al. proposed the left atrial volume to be a better predictor for AF than one-dimensional parameters due to its higher accuracy [6]. P-terminal force in V1 (PTFV1) is considered as an electrocardiogram (ECG) indicator of left atrial enlargement and was associated with AF risk in multiple studies [7]. Elevated natriuretic peptides were predictive of death and cardiovascular events in the Framingham Heart Study [8]. Furthermore, they have been shown to be an independent risk factor for AF in the Cardiovascular Health Study [9].

The current concept of a left atrial disease does not include excessive supraventricular ectopic activity (ESVEA), although ESVEA increased the risk for AF in the population-based Copenhagen Holter Study, in patients with cardiovascular risk factors and patients post stroke [10–13].

We therefore hypothesized that not all of the currently described components associated with a left atrial disease do have an independent impact on AF risk and that ESVEA is a major independent risk factor for AF development.

2. Methods

Patients

This analysis was conducted in a subgroup of participants of the non-interventional Diast-CHF (Prevalence and clinical course of diastolic dysfunction and diastolic heart failure) trial. The design, inclusion and exclusion criteria of the Diast-CHF trial have been described previously [14]. In summary, patients with at least one cardiovascular risk factor for heart failure with preserved ejection fraction aged 50 to 85 years were included in the Diast-CHF trial. The patients had at least one of the following risk factors: hypertension, diabetes mellitus, sleep apnoea syndrome or atherosclerotic disease. Patients who participated in the 7-day Holter ECG substudy (n = 162) qualified for the current analysis [14]. All participants underwent medical history, physical examination, a 12-lead ECG and transthoracic echocardiography at baseline. Follow-up investigations were conducted after one, two, five, nine and ten years. Patients with AF in medical history or in 12-lead- or Holter-ECG at baseline were excluded from further analyses. The protocol of the Diast-CHF study was approved by the responsible
ethics committee of University Medicine Göttingen and complies with the Declaration of Helsinki. All patients gave their informed written consent.

**N-terminal pro-B-type natriuretic peptide (NT-proBNP)**

NT-proBNP plasma levels were measured using a sandwich immunoassay (Roche Diagnostics, Mannheim, Germany). For the diagnosis of a left atrial disease, NT-proBNP > 250 pg/ml was considered abnormal [15]. For multivariable analysis, we used log-transformed NT-proBNP.

**12-lead ECG**

12-lead ECGs were obtained using ECG machines calibrated at 10 mm/mV with a speed of 50 mm/s. PTFV₁ was measured as described previously in two consecutive p-waves and mean PTFV₁ was calculated [16]. PTFV₁ > 4000 ms·μV was defined as abnormal according to previously published data [17].

**Echocardiography**

Echocardiography was performed by experienced physicians using a Sonos 5500 (Hewlett-Packard, Andover, MA, USA) according to the guidelines of the American Society of Echocardiography and as previously described [18]. Indexed left atrial volume (LAVI) was calculated using left atrial volume and body surface area [19].

**Holter ECG**

A dual-channel Holter ECG was recorded with digital portable recorders (Lifecard CF, Del Mar Reynolds Medical Ltd, Hertford, UK) for seven consecutive days. Analyses were performed with Pathfinder digital (Software Version V8.602, Del Mar Reynolds Medical Ltd). Holter-ECG were systematically screened for AF by an experienced investigator. Excessive supraventricular ectopic activity was defined as >720 premature atrial contractions (PAC) or at least one atrial run > 20 beats per day according to data from the Copenhagen Holter study and used as a categorical variable for survival analysis [10]. For multivariable analysis, we used log-transformed PAC.

**Definition of left atrial disease**

Left atrial disease was defined as described previously as either PTFV₁ > 4000 ms·μV, NT-proBNP > 250 pg/ml or LAVI > 35 ml/m² [15].

**Endpoint assessment**

Patients received ECGs at the regular study visits. If patients reported AF episodes outside of the study visits, original documentation (e.g., ECG tracings, hospital letters) was requested and critically reviewed. AF was defined according to current guidelines as any episode of at least 30 seconds during Holter ECG monitoring or documentation on a 12-channel ECG strip [20]. An experienced cardiologist, blinded to all other clinical data, validated all AF episodes.

**Statistical analysis**

Continuous variables are given as mean ± standard deviation if normally distributed and as median and interquartile ranges between the 25th and 75th centile if skew distributed. Categorical variables are shown as absolute numbers (%). Continuous data were compared by Student’s
t-test, skew distributed data by Mann-Whitney-U-Test and frequencies by Fisher’s exact test or chi-square test.

AF free survival was calculated using Kaplan-Meier plots with log-rank test for $PTFV_1 > 4000 \text{ ms}^2 \mu \text{V}$, $NT-proBNP > 250 \text{ pg/ml}$, $LAVI > 35 \text{ ml/m}^2$ and ESVEA. Thereafter, multivariable analysis using Cox-regression was performed for all parameters associated with AF free survival and possible confounders, i.e., parameters with significant differences in baseline characteristics. Skew distributed parameters were log-transformed.

All tests were performed with SPSS Statistics 25.0 (IBM, Chicago, Illinois, USA). P-values < 0.05 were considered to be significant.

3. Results

Study population

Of the 162 patients with evaluable Holter ECG, four patients had AF in medical history and ten patients in baseline Holter. 148 were included in the present analysis. 110 patients completed follow-up after 10 years while 18 patients died, and 20 patients were lost to follow-up. The study flow chart is shown in Fig 1.

Distribution of parameters of left atrial disease and baseline characteristics

Eighty-nine patients had at least one parameter of left atrial disease while eight patients fulfilled all criteria. Sixty-six patients (45%) had abnormal $PTFV_1$, 38 patients (26%) had elevated $NT-proBNP$, 22 patients (15%) had $LAVI > 35 \text{ ml/m}^2$ (Fig 2).

Table 1 shows the baseline characteristics of patients with at least one parameter of left atrial disease compared to those without. Patients with signs of left atrial disease were significantly older, had a higher prevalence of coronary artery disease, higher systolic blood pressure at baseline and a prolonged PQ-interval. No significant differences were found for indexed left ventricular mass and echocardiographic diastolic dysfunction measured as $E/e'$.

Risk of atrial fibrillation in 10-year-follow-up

After ten years of follow-up, AF was newly detected in twelve patients (13.4%) with signs of left atrial disease and two patients (3.4%) without signs of left atrial disease ($p = 0.04$). In univariate analysis, $NT-proBNP$ level $\leq 250 \text{ pg/ml}$ ($p = 0.01$) and $LAVI \leq 35 \text{ ml/m}^2$ ($p = 0.01$), showed a significant association with AF free survival, while $PTFV_1$ did not ($p = 0.60$). ESVEA was significantly associated with a reduction in AF-free survival ($p = 0.02$). Kaplan-Meier-plots are shown in Fig 3.

In multivariable analysis, significant associations with AF-free survival were found for log-transformed $NT-proBNP$ and log-transformed PAC, but not $LAVI$ (see Table 2).

4. Discussion

We studied the impact of parameters of a left atrial disease on the risk of atrial fibrillation in patients with cardiovascular risk factors. The main findings are that $NT-proBNP$ and premature atrial contractions were independently associated with recurrent AF occurrence but not the left atrial volume index or the P-terminal force in lead $V_1$.

Our finding of a predictive value of natriuretic peptides to identify patients at risk for paroxysmal AF is corroborated by findings in other cohorts, e.g. population-based and patients immediately post stroke [21, 22]. In Diast-CHF, we previously showed that natriuretic peptides are predictive for current paroxysmal AF and now extend these data on 10-year long-term risk of AF.
Left atrial enlargement has been shown to be predictive for AF in patients with cardiovascular risk factors, population based cohorts and patients post stroke [4, 5, 23]. Most studies investigated left atrial diameter (LAD), not left atrial volume, although LAVI has been recognized as a better predictor of AF than LAD or indexed LAD [6]. However, most studies performed multivariable analyses with echocardiographic measurements and clinical covariates but did not analyze ESVEA and PTFV1. We observed an association between incident AF and LAVI in univariable analysis, but this association disappeared after including ESVEA and NT-proBNP in a multivariable model. LAVI and NT-proBNP are often correlated and bare similar diagnostic information [24]. Our results imply that LAVI does not have incremental diagnostic value over NT-proBNP for the prediction of AF. Pagola et al. came to a similar conclusion following

![Study flow chart](https://doi.org/10.1371/journal.pone.0266848.g001)
The comparative analysis of NT-proBNP and LAVI as risk predictors for AF in patients after cryptogenic stroke [25].

Our analysis did not find an impact of electrocardiographic abnormality, i.e., increased PTFV$_1$ on AF-free survival. In contrast, several analyses have shown significant associations of PTFV$_1$ with the risk of AF [17, 26]. This discrepancy is probably due to different patient characteristics of these north American cohort studies compared to our study, which included Caucasians only. PTFV$_1$ was highly predictive of AF in black patients, but only moderately in white patients [26]. This race-dependent difference could be a possible explanation for the failure of PTFV$_1$ as an AF risk predictor in our study. Moreover, the clinical utility of PTFV$_1$ may be limited because of its poor inter-observer- and inter-P-waves-reliability [27].

Excessive supraventricular ectopic activity was associated with the 10-year risk for AF. Consistent with our findings, ESVEA was predictive of AF post stroke and in the population based Copenhagen Holter study [10, 12, 13].

An independent predictive value of ESVEA and NT-proBNP on AF risk was shown in a population-based Swedish cohort, but a direct comparison of four potential components of left atrial disease (NT-proBNP, left atrial size, PTFV$_1$ and ESVEA) on the risk of AF development has not been performed yet [28]. From a methodological standpoint, it is suggestive that some components may bear similar diagnostic information. Our analysis found that PTFV$_1$ and left atrial size do not give incremental predictive information on the risk of AF. In a multivariable analysis of data from the Framingham Heart Study (PTFV$_1$ was not significantly associated with AF [29]). Rasmussen et al. evaluated different P-wave-indices from the Copenhagen Holter study and incorporated them into a clinical risk score developed from data of the Framingham Heart Study but could not show an improved AF risk discrimination for PTFV$_1$ [30]. Adding echocardiographic measurements to a clinical AF risk score showed a slight

---

**Fig 2. Venn diagram of distribution of left atrial disease parameters.** 66 patients (45%) had abnormal PTFV$_1$ (green circle), 36 patients (26%) had elevated plasma levels of NTproBNP (blue circle), and 22 patients (15%) had elevated left atrial volume index (red circle). LAVI = indexed left atrial volume; PTFV$_1$ = P-terminal force in V$_1$; NT-proBNP = N-terminal pro-B-type natriuretic peptide.

https://doi.org/10.1371/journal.pone.0266848.g002
Table 1. Baseline characteristics for patients with and without signs of left atrial disease.

|                                      | No signs of left atrial disease (n = 59) | Signs of left atrial disease (n = 89) | p     |
|--------------------------------------|----------------------------------------|--------------------------------------|-------|
| Age (years)                          | 62.0 ± 7.2                              | 65.5 ± 7.3                           | 0.01' |
| Male gender                          | 33 (55.9)                               | 54 (60.7)                            | 0.57  |
| Systolic blood pressure (mmHg)       | 143.3 ± 18.8                            | 150.6 ± 20.4                         | 0.03' |
| Diastolic blood pressure (mmHg)      | 84.1 ± 12.0                             | 84.4 ± 12.2                          | 0.91  |
| Heart rate (/min)                    | 74.1 ± 14.0                             | 70.9 ± 13.9                          | 0.17  |
| BMI (kg/m²)                          | 29.2 ± 5.1                              | 28.7 ± 4.0                           | 0.55  |
| Comorbidities                        |                                        |                                      |       |
| Hypertension                         | 54 (91.5)                               | 82 (92.1)                            | 1.00  |
| Heart failure                        | 4 (6.8)                                 | 5 (5.6)                              | 1.00  |
| Diabetes mellitus                    | 18 (30.5)                               | 25 (28.1)                            | 0.75  |
| Hyperlipidaemia                      | 25 (42.4)                               | 44 (49.4)                            | 0.40  |
| Sleep apnea                          | 3 (5.1)                                 | 7 (7.9)                              | 0.74  |
| Coronary artery disease              | 7 (11.9)                                | 24 (27.0)                            | 0.03' |
| Myocardial infarction                | 5 (8.5)                                 | 12 (13.5)                            | 0.35  |
| Periphery artery disease             | 3 (5.1)                                 | 2 (2.2)                              | 0.39  |
| Stroke/TIA                           | 4 (6.8)                                 | 1 (1.1)                              | 0.08  |
| CHA²DS²-VASc Score                   | 2 [1;3]                                 | 3 [2;3]                              | 0.21  |
| Medication                           |                                        |                                      |       |
| Beta-blocker                         | 26 (44.1)                               | 41 (46.1)                            | 0.81  |
| AT1-Antagonists                      | 12 (20.3)                               | 10 (11.2)                            | 0.13  |
| ACE-Inhibitors                       | 29 (49.2)                               | 45 (50.6)                            | 0.87  |
| Thiazide diuretics                   | 29 (49.2)                               | 41 (46.1)                            | 0.71  |
| Loop diuretics                       | 5 (8.5)                                 | 15 (16.9)                            | 0.14  |
| MRA                                  | 1 (1.7)                                 | 0 (0)                                | 0.40  |
| CCB                                  | 8 (13.6)                                | 20 (22.5)                            | 0.18  |
| Laboratory                           |                                        |                                      |       |
| Creatinine (mg/dl)                   | .96 ± .17                               | 1.02 ± .35                           | 0.22  |
| Hemoglobine (g/dl)                   | 14.38 ± 1.17                            | 14.10 ± 1.20                         | 0.18  |
| TSH (μU/ml)                          | 1.14 ± .71                              | 1.03 ± 1.19                          | 0.51  |
| 12-lead-ECG                          |                                        |                                      |       |
| PQ (ms)                              | 162.2 ± 20.4                            | 171.4 ± 28.9                         | 0.03' |
| QRS (ms)                             | 91.4 ± 12.9                             | 92.3 ± 13.3                          | 0.68  |
| QT interval (ms)                     | 382.4 ± 27.5                            | 392.2 ± 36.1                         | 0.07  |
| QTc Bazett (ms)                      | 402.5 ± 23.3                            | 403.6 ± 26.3                         | 0.79  |
| Echocardiography                     |                                        |                                      |       |
| LVEF (%)                             | 60.4 ± 5.9                              | 60.2 ± 6.7                           | 0.84  |
| Left atrial diameter (mm)            | 39.4 ± 4.3                              | 42.0 ± 5.6                           | 0.01' |
| A’ (m/s)                             | 10.2 ± 2.1                              | 10.0 ± 2.3                           | 0.70  |
| Left ventricular mass index (g/m²)   | 75.8 ± 30.8                             | 84.2 ± 38.3                          | 0.16  |
| E/e’ > 14                            | 2 (3.4%)                                | 10 (11.2%)                           | 0.09  |

Baseline characteristics; n = 148; left atrial disease is defined as either LAVI > 35 ml/m² or PTFV₁ ≤ -4000 μV or NT-proBNP > 250 pg/ml; BMI = Body mass index; TIA = transient ischaemic attack; PTFV₁ = P-terminal force in V₁; NT-proBNP = N-terminal pro-B-type natriuretic peptide; MRA = mineralocorticoid receptor antagonists; CCB = calcium-channel blockers; TSH = Thyroid-stimulating hormone; ECG = electrocardiogram; LVEF = Left ventricular ejection fraction; Values are given as mean ± standard deviation, median [interquartile range] or n (%)

https://doi.org/10.1371/journal.pone.0266848.t001
impact on the risk assessment [31]. Interestingly, in 5120 participants in the Cardiovascular Health Study, left atrial dimension was the only parameter of left atrial disease parameter not significant associated with stroke risk—even if ESVEA was not included in the analysis [3].

Another interesting finding is that age did not give predictive information for AF. A potential explanation is that all four potential components of left atrial disease were positively correlated with age [32–35]. This may explain why age per se did not bear incremental diagnostic information.

5. Strengths and limitations

Our analysis is limited by a medium sample size and a moderate number of patients lost to follow-up, which reduces the power of our analysis. Moreover, in the Diast-CHF-study, cardiovascular imaging was achieved by transthoracic echocardiography, not by cardiac magnetic resonance imaging (CMR). This can be considered as a limitation as CMR has the potential to acquire more accurate data regarding the left atrial volume and to quantify left-atrial fibrosis.

| Parameter | Hazard Ratio | 95% Confidence Interval | p-Value |
|-----------|--------------|-------------------------|---------|
| logPAC    | 2.66         | 1.25                    | 10.15   | 0.01   |
| logNT-proBNP | 3.56          | 1.33                    | 5.31    | 0.04   |

NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAC = premature atrial contractions.
Our analysis is also limited by lacking a time-dependent analysis of the development of different parameters of left atrial disease. Still, the detailed and comprehensive characterization of the patient population is a strength of the analysis. The 7-day Holter ECG prior to study inclusion is minimizes the risk of the inclusion of patients with undetected underlying and easily detectable AF.

6. Conclusion
In summary, out of four potential predictors for incident atrial fibrillation, only the excessive supraventricular ectopic activity and NT-proBNP were independently associated with incident atrial fibrillation during a 10-year follow-up. ESVEA should be considered as a potential criterion for a left atrial disease. Further studies are wanted to validate these findings in different cohorts and prospectively.

Supporting information
S1 Data.
(XLSX)

Author Contributions
Conceptualization: Tobias Uhe, Rolf Wachter.
Data curation: Tobias Uhe, Rolf Wachter.
Formal analysis: Tobias Uhe.
Funding acquisition: Rolf Wachter.
Investigation: Tobias Uhe, Rolf Wachter.
Methodology: Tobias Uhe.
Project administration: Rolf Wachter.
Resources: Rolf Wachter.
Supervision: Rolf Wachter.
Visualization: Tobias Uhe.
Writing – original draft: Tobias Uhe.
Writing – review & editing: Tobias Uhe, Tina Stegmann, Romy Langhammer, Nikolaos Dagres, Ulrich Laufs, Rolf Wachter.

References
1. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRSA/APHRS/SOLAEC expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Heart Rhythm. 2017; 14: e3–e40. https://doi.org/10.1016/j.hrthm.2016.05.028 PMID: 27320515
2. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271: 840–844. PMID: 8114238
3. Kamel H, Bartz TM, Elkind MSV, Okin PM, Thacker EL, Patton KK, et al. Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study). Stroke. 2018; 49: 980–986. https://doi.org/10.1161/STROKEAHA.117.020059 PMID: 29535268
4. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and Risk Factors for Atrial Fibrillation in Older Adults. Circulation. 1997; 96: 2455–2461. https://doi.org/10.1161/01. cir.96.7.2455 PMID: 9337224
5. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation. 1994; 89: 724–730. https://doi.org/10.1161/01.cir.89.2.724 PMID: 8313561

6. Tsang TSM, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, et al. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clinic Proceedings. 2001; 76: 467–475. https://doi.org/10.4065/76.5.467 PMID: 11357793

7. Huang Z, Zheng Z, Wu B, Tang L, Xie X, Dong R, et al. Predictive value of P wave terminal force in lead V1 for atrial fibrillation: A meta-analysis. Ann Noninvasive Electrocardiography. 2020; 25. https://doi.org/10.1111/anec.12739 PMID: 32022368

8. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death. N Engl J Med. 2004; 350: 655–663. https://doi.org/10.1056/NEJMoa031994 PMID: 14960742

9. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gotttdiener JS, et al. N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation: The Cardiovascular Health Study. Circulation. 2009; 120: 1768–1774. https://doi.org/10.1161/CIRCULATIONAHA.109.873265 PMID: 19841297

10. Binici Z, Intzilakis T, Nielsen OW, Keber L, Saajdeh A. Excessive Supraventricular Ectopic Activity and Increased Risk of Atrial Fibrillation and Stroke. Circulation. 2010; 121: 1904–1911. https://doi.org/10.1161/CIRCULATIONAHA.109.874988 PMID: 20404258

11. Kochhäuser S, Dechering DG, Dittrich R, Reineke F, Ritter MA, Ramtin S, et al. Supraventricular Premature Beats and Short Atrial Runs Predict Atrial Fibrillation in Continuously Monitored Patients With Cryptogenic Stroke. Stroke. 2014; 45: 884–886. https://doi.org/10.1161/STROKEAHA.113.003788 PMID: 24425117

12. Weber-Krüger M, Gröschel K, Mende M, Seegers J, Lahno R, Haase B, et al. Excessive Supraventricular Ectopic Activity Is Indicative of Paroxysmal Atrial Fibrillation in Patients with Cerebral Ischemia. Arumugam TV, editor. PLoS ONE. 2013; 8: e67602. https://doi.org/10.1371/journal.pone.0067602 PMID: 23840747

13. Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, et al. Atrial Premature Beats Predict Atrial Fibrillation in Cryptogenic Stroke: Results From the EM BRACE Trial. Stroke. 2015; 46: 936–941. https://doi.org/10.1161/STROKEAHA.115.008714 PMID: 25700289

14. Seegers J, Zabel M, Grueter T, Ammermann A, Weber-Kruger M, Edelmann F, et al. Natriuretic peptides for the detection of paroxysmal atrial fibrillation. Open Heart. 2015; 2: e000182. https://doi.org/10.1136/openhrt-2014-000182 PMID: 26288739

15. Kamel H, Longstreth W, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. International Journal of Stroke. 2019; 14: 207–214. https://doi.org/10.1111/ijso.12739 PMID: 30196789

16. Magnani JW, Mazzioli MJ, Sullivan LM, Williamson M, Ellinor PT, Benjamin EJ. P-Wave Indices, Distribution and Quality Control Assessment (from the Framingham Heart Study). Annals of Noninvasive Electrocardiology. 2010; 15: 77–84. https://doi.org/10.1111/j.1542-474X.2009.00343.x PMID: 20146786

17. Kamel H, Soliman EZ, Heckbert SR, Kronmal RA, Longstreth WT, Nazarian S, et al. P-Wave Morphology and the Risk of Incident Ischemic Stroke in the Multi-Ethnic Study of Atherosclerosis. Stroke. 2014; 45: 2786–2788. https://doi.org/10.1161/STROKEAHA.114.006364 PMID: 25052322

18. Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düneng H, Scherer M, et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia. 2010; 53: 1331–1340. https://doi.org/10.1007/s00125-010-1718-8 PMID: 20386878

19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2005; 18: 1440–1463. https://doi.org/10.1016/j.echo.2005.10.005 PMID: 16376782

20. Hindricks G, Potpara T, Dagenes N, Arbeo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2021; 42: 373–498. https://doi.org/10.1093/eurheartj/ehaa612 PMID: 32860505

21. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, et al. Relations of Biomarkers of Distinct Pathophysiological Pathways and Atrial Fibrillation Incidence in the Community.
22. Wasser K, Weber-Krüger M, Gröschel S, Uphaus T, Liman J, Hamann GF, et al. Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After Stroke: A Subanalysis of the Find-AF RANDOMISED Trial. Stroke. 2020; 51: 395–401. https://doi.org/10.1161/STROKEAHA.119.026496 PMID: 3180354

23. Poli S, Diedler J, Härtig F, Götz N, Bauer A, Sachse T, et al. Insertable cardiac monitors after cryptogenic stroke—a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol. 2016; 23: 375–381. https://doi.org/10.1111/ene.12843 PMID: 26470084

24. Abbasi SA, Shah RV, McNulty SE, Hernandez AF, Semigran MJ, Lewis GD, et al. Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy. Abete P, editor. PLoS ONE. 2016; 11: e0164914. https://doi.org/10.1371/journal.pone.0164914 PMID: 27812147

25. Pagola J, Juega J, Francisco-Pascual J, Bustamante A, Penalba A, Pala E, et al. Predicting Atrial Fibrillation with High Risk of Embolization with Atrial Strain and NT-proBNP. Transl Stroke Res. 2020 [cited 8 Jul 2021]. https://doi.org/10.1007/s12975-020-00873-2 PMID: 33184686

26. Soliman EZ, Prineas RJ, Case LD, Zhang Z, Goff DC. Ethnic Distribution of ECG Predictors of Atrial Fibrillation and Its Impact on Understanding the Ethnic Distribution of Ischemic Stroke in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 2009; 40: 1204–1211. https://doi.org/10.1161/STROKEAHA.108.534735 PMID: 19213946

27. Sajeev JK, Koshy AN, Dewey H, Kalman JM, Bhatia M, Roberts L, et al. Poor reliability of P-wave terminal force V1 in ischemic stroke. Journal of Electrocardiology. 2019; 52: 47–52. https://doi.org/10.1016/j.jelectrocard.2018.11.007 PMID: 30476638

28. Xiao J, Persson AP, Engström G, Johnson LSB. Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study. BMC Cardiovasc Disorders. 2021; 21: 134. https://doi.org/10.1186/s12872-021-01942-6 PMID: 33711943

29. Magnani JW, Zhu L, Lopez F, Pencina MJ, Agarwal SK, Soliman EZ, et al. P-wave indices and atrial fibrillation: Cross-cohort assessments from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study. American Heart Journal. 2015; 169: 53–61.e1. https://doi.org/10.1016/j.ahj.2014.10.009 PMID: 25497248

30. Rasmussen MU, Kumarathurai P, Fabricius-Bjerre A, Larsen BS, Domínguez H, Davidsen U, et al. P-wave indices as predictors of atrial fibrillation. Ann Noninvasive Electrocardiol. 2020; 25. https://doi.org/10.1111/anec.12751 PMID: 32274994

31. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. The Lancet. 2009; 373: 739–745. https://doi.org/10.1016/S0140-6736(09)60443-8 PMID: 19249635

32. Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, et al. Reference Limits for N-Terminal-pro-B-Type Natriuretic Peptide in Healthy Individuals (from the Framingham Heart Study). The American Journal of Cardiology. 2011; 108: 1341–1345. https://doi.org/10.1016/j.amjcard.2011.06.057 PMID: 21864812

33. Conen D, Adam M, Roche F, Barthelemy J-C, Felber Dietrich D, Imboden M, et al. Premature Atrial Contractions in the General Population: Frequency and Risk Factors. Circulation. 2012; 126: 2302–2308. https://doi.org/10.1161/CIRCULATIONAHA.112.112300 PMID: 23048073

34. Okin PM, Kamel H, Jfeldsen SE, Devereux RB. Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy. Journal of Hypertension. 2016; 34: 1831–1837. https://doi.org/10.1097/HJH.0000000000000989 PMID: 27254312

35. D’Andrea A, Riegler L, Rucco MA, Cocchia R, Scarafilli R, Salerno G, et al. Left Atrial Volume Index in Healthy Subjects: Clinical and Echocardiographic Correlates. Echocardiography. 2013; 30: 1001–1007. https://doi.org/10.1111/echo.12217 PMID: 23594028